DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,457,767 | -0.8% | 211,438 | -4.0% | 0.34% | +19.4% |
| Q2 2023 | $52,881,170 | -11.1% | 220,338 | -6.7% | 0.29% | -13.3% |
| Q1 2023 | $59,490,258 | -7.2% | 236,035 | -2.3% | 0.33% | -7.8% |
| Q4 2022 | $64,114,481 | -2.8% | 241,559 | -5.4% | 0.36% | -7.7% |
| Q3 2022 | $65,966,000 | +3.0% | 255,394 | +1.1% | 0.39% | +11.1% |
| Q2 2022 | $64,020,000 | -1.5% | 252,525 | +14.0% | 0.35% | +11.1% |
| Q1 2022 | $64,984,000 | -10.1% | 221,538 | +0.8% | 0.32% | -5.1% |
| Q4 2021 | $72,316,000 | +3.5% | 219,798 | -4.3% | 0.33% | -4.6% |
| Q3 2021 | $69,904,000 | +10.6% | 229,616 | -2.5% | 0.35% | +9.7% |
| Q2 2021 | $63,179,000 | +17.9% | 235,426 | -1.1% | 0.32% | +7.4% |
| Q1 2021 | $53,567,000 | -2.9% | 237,992 | -4.2% | 0.30% | -10.8% |
| Q4 2020 | $55,161,000 | +2.7% | 248,318 | -0.4% | 0.33% | -5.1% |
| Q3 2020 | $53,708,000 | +22.9% | 249,422 | +0.9% | 0.35% | +10.1% |
| Q2 2020 | $43,705,000 | +31.1% | 247,156 | -4.3% | 0.32% | +15.6% |
| Q1 2020 | $33,343,000 | -22.4% | 258,172 | -7.7% | 0.28% | -0.7% |
| Q4 2019 | $42,952,000 | +8.6% | 279,852 | +2.2% | 0.28% | 0.0% |
| Q3 2019 | $39,552,000 | -6.6% | 273,849 | -7.5% | 0.28% | 0.0% |
| Q2 2019 | $42,327,000 | +4.9% | 296,157 | -3.1% | 0.28% | -2.5% |
| Q1 2019 | $40,364,000 | +24.5% | 305,743 | -2.8% | 0.28% | +10.1% |
| Q4 2018 | $32,431,000 | -5.7% | 314,499 | -0.6% | 0.26% | +6.6% |
| Q3 2018 | $34,390,000 | +9.3% | 316,490 | -0.8% | 0.24% | +3.0% |
| Q2 2018 | $31,478,000 | -2.6% | 318,992 | -3.3% | 0.24% | -4.5% |
| Q1 2018 | $32,314,000 | +5.7% | 330,038 | +1.0% | 0.25% | +2.1% |
| Q4 2017 | $30,560,000 | +8.7% | 326,632 | -0.4% | 0.24% | +0.8% |
| Q3 2017 | $28,127,000 | +1.6% | 327,893 | -0.0% | 0.24% | -3.6% |
| Q2 2017 | $27,676,000 | -1.9% | 327,949 | -0.6% | 0.25% | -5.7% |
| Q1 2017 | $28,221,000 | +7.4% | 329,957 | -2.3% | 0.26% | +3.1% |
| Q4 2016 | $26,277,000 | +2.2% | 337,576 | +2.9% | 0.26% | +2.0% |
| Q3 2016 | $25,716,000 | -21.4% | 328,056 | +1.3% | 0.25% | -24.9% |
| Q2 2016 | $32,708,000 | -8.9% | 323,844 | -14.4% | 0.33% | -15.9% |
| Q1 2016 | $35,886,000 | +1.3% | 378,309 | -0.8% | 0.40% | -2.9% |
| Q4 2015 | $35,412,000 | +7.0% | 381,268 | -1.8% | 0.41% | +2.8% |
| Q3 2015 | $33,096,000 | -2.1% | 388,402 | -1.7% | 0.40% | +1.3% |
| Q2 2015 | $33,813,000 | +3.9% | 395,055 | -0.6% | 0.39% | -1.5% |
| Q1 2015 | $32,540,000 | -51.5% | 397,414 | -49.2% | 0.40% | -21.0% |
| Q4 2014 | $67,061,000 | +139.1% | 782,419 | +112.0% | 0.50% | +3.5% |
| Q3 2014 | $28,042,000 | -2.5% | 369,069 | +1.1% | 0.49% | -8.6% |
| Q2 2014 | $28,751,000 | +8.8% | 365,184 | +3.6% | 0.53% | -5.3% |
| Q1 2014 | $26,428,000 | +3.6% | 352,370 | +6.7% | 0.56% | -35.1% |
| Q4 2013 | $25,499,000 | +1280.6% | 330,294 | +1139.4% | 0.87% | +1371.2% |
| Q3 2013 | $1,847,000 | -92.2% | 26,650 | -92.9% | 0.06% | -90.6% |
| Q2 2013 | $23,709,000 | – | 374,551 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |